Trabectedine ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
159Xeroderma pigmentosum1

159. Xeroderma pigmentosum


Clinical trials : 10 Drugs : 18 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 15
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022968-13-BE
(EUCTR)
16/03/201104/01/2011Study of the medicinal product Trabectedin in Patients with AdvancedBreast Carcinoma.Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderma Pigmentosum G Gene (XPG) Advanced Breast Carcinoma
MedDRA version: 14.0;Level: LLT;Classification code 10006204;Term: Breast carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Trade Name: Yondelis 0.25 mg powder for concentrate for solution for infusion.
INN or Proposed INN: trabectedine
Trade Name: Yondelis 1 mg powder for concentrate for solution for infusion.
INN or Proposed INN: trabectedine
Pharma Mar, S.A. Sociedad UnipersonalNULLNot RecruitingFemale: yes
Male: yes
100Phase 2Spain;Belgium